Natera (NTRA) reported $367.74 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 52.1%. EPS of -$0.56 for the same period compares to -$1.23 a year ago.The reported revenue represents a surprise of +18.04% over the Zacks Consensus Estimate of $311.54 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +22.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Exhibit 99.1 Natera Reports First Quarter 2024 Financial Results AUSTIN, Texas, May 9, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. "We had an excellent start to the year, driving robust volume, revenue and margin growth and achieving cash flow breakeven earlier than expected," said Steve Chapman, chief executive officer of Natera. "We continued to deliver on our mission ...

Since inception, Natera (NASDAQ:NTRA) has incurred sustained losses, with their cash burn rate being one of the largest concerns to investors. However, the company seems to be on the verge of becoming profitable for the first time in its history. In my opinion, this is mostly due to the growth of the personalised medicines, particularly in oncology, together with the recently approved biomarkers law in 13 U.S. states. Thus, I consider that Natera as a “buy,” despite the risks associated with it. Personalise ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond James 45th Annual Institutional Investors Conference Tuesday, March 5 at 2:15 pm ET | 11:15 am PT in Orlando, FL TD Cowen 44th Annual Health Care Conference Wednesday, March 6 at 9:50 am ET | 6:50 am PT in Boston, MA A live webcast and audio archive of each event may be accessed through the investor rela ...

Natera (NTRA) reported $311.11 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 43.2%. EPS of -$0.64 for the same period compares to -$1.37 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $300.38 million, representing a surprise of +3.57%. The company delivered an EPS surprise of +12.33%, with the consensus EPS estimate being -$0.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) State or Other Jurisdiction of Incorpora ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX) in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting. These determinations add to a growing l ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2023, after the market close on Feb. 28, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera’s Fourth Quarter and Year-End 2023 Financial Results Date: Wednesday, Feb. 28, 2024 Time: ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in endometrial cancer. The full study can be found here. Endometrial cancer (EC) is the most common gynecologic malignancy in the United States. Disease incidence has been rising, but mortality has been rising even faster, potentially due to a highe ...